Melanotan I is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Selectively binds MC1R on melanocytes, triggering the cAMP-dependent signaling cascade that increases MITF transcription factor activity. This upregulates tyrosinase enzyme expression and melanin synthesis, producing skin darkening without requiring UV exposure.
How Does Melanotan I Work in the Body?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation.
Understanding its mechanism of action helps researchers design protocols and predict outcomes.
What Is the Primary Mechanism of Melanotan I?
Selectively binds MC1R on melanocytes, triggering the cAMP-dependent signaling cascade that increases MITF transcription factor activity. This upregulates tyrosinase enzyme expression and melanin synthesis, producing skin darkening without requiring UV exposure.
This mechanism operates at the cellular level and influences downstream pathways that produce the observable effects researchers study.
What Biological Pathways Does Melanotan I Affect?
As a Melanocortin-1 receptor (MC1R) agonist, Melanotan I interacts with specific receptors and signaling cascades. These pathways are responsible for the compound's effects on skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
The multi-pathway activity is what gives Melanotan I its broad potential application range — each pathway contributes to different aspects of the overall effect profile.
How Quickly Does Melanotan I's Mechanism Take Effect?
With a half-life of ~2 hours circulating; implant provides 2-month depot release, Melanotan I begins interacting with its target receptors within minutes of administration. However, the downstream biological effects take longer to manifest — typically days to weeks depending on the application.
Standard cycles run 60-day implant cycles; 4-8 weeks injection cycles because that's the timeframe needed for the mechanism to produce measurable, cumulative results.
What Does the Research Say?
Multiple Phase II/III clinical trials. FDA-approved in 2019 for erythropoietic protoporphyria (EPP) as Scenesse — the only Melanotan with full regulatory approval and extensive human safety data.
The only Melanotan analog with FDA approval and extensive Phase III clinical trial data — far better characterized for safety than the more popular (but more dangerous) Melanotan II.
Bottom Line on Melanotan I's Mechanism
Melanotan I works through melanocortin-1 receptor (mc1r) agonist activity to influence skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning. Its mechanism involves multiple pathways, which is why it shows potential across several research applications.
See our Melanotan I benefits guide for how this mechanism translates to practical outcomes.
Complete Guide
Melanotan I : Benefits, Dosage, Side Effects & Research
Related Reading
- Melanotan I Dosage Guide
- Melanotan I Benefits
- Melanotan I Side Effects
- Melanotan I Stacking Guide
- Melanotan I Cycle Guide
- Melanotan I Research
Calculate Your Melanotan I Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Melanotan I.
Open Calculator →Research-Grade Sourcing
If you're going to research Melanotan I, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
What is the recommended Melanotan I dosage?
Common dosages: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Cycle length: 60-day implant cycles; 4-8 weeks injection cycles. Half-life: ~2 hours circulating; implant provides 2-month depot release. Use our peptide calculator for exact reconstitution math.
What are the side effects of Melanotan I?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Is Melanotan I safe?
Melanotan I has shown a preliminary safety profile in research. FDA-approved as Scenesse for EPP only (prescription). Not approved for cosmetic tanning. All research should follow appropriate safety protocols.